undamentalytics Newsletter
Sign in

ARS Pharmaceuticals, Inc. income statement

In fiscal 2025, ARS Pharmaceuticals, Inc. reported revenue of $84.3m, down 5.5% on the year before, operating income of −$179m (a -212.9% margin) and net income of −$171m, or −$1.74 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue6108984117
Cost of revenue——0———
Gross profit——0———
Research and development201820201315
Selling, general and administrative—14772230284
General and administrative5—————
Operating income−19−36−68−3−179−216
Net interest income0—————
Income before tax——−548−171—
Income tax0000−0—
Net income−20−35−548−171−215
Diluted EPS−$0.70−$0.87−$0.57$0.08−$1.74−$2.17
Diluted shares (average)29m40m95m102m99m99m
EBITDA−19−35−67−3−178−215

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: RCUS vs SPRYMESO vs SPRYSPRY vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ARS Pharmaceuticals, Inc.